159877-48-2Relevant academic research and scientific papers
BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonist
Fisher, Liesl G.,Sher, Philip M.,Skwish, Stephen,Michel, Inge M.,Seiler, Steven M.,Dickinson, Kenneth E. J.
, p. 2253 - 2258 (2007/10/03)
Novel heterocyclic β3 adrenergic receptor agonists were prepared and evaluated for their ability to bind to human β1, β2, and β3 adrenergic receptors. Stimulatory effects on the β3 adrenergic receptor were also measured. BMS-187257 (4b) was found to be a potent and selective β3 agonist.
THIAZOLE AND OXAZOLE-BASED BETA3 ADRENERGIC RECEPTOR AGONISTS
-
, (2008/06/13)
Compounds having the formula STR1 and pharmaceutically acceptable salts thereof where A is STR2 R 3 is--(CH 2) n--or in the case where R 2 is STR3 R 3 in addition to the above may be STR4 R 4 is hydroxy, alkoxy, amino, alkylamino or dialkylamino; R 5 is hydrogen, fluorine, chlorine, bromine, iodine,--CN, CF 3, lower alkyl, lower alkoxy, cycloalkyl or aryl;R 6 is lower alkyl, cycloalkyl or aryl;R 7, R 7 ', R 8 and R. sub.8 ' are independently hydrogen or a lower alkyl or R. sub.7 and R 8 may together be CH 2 CH 2 ; Z is hydrogen or STR5 m is an integer of 1 or 2; n is zero or an integer of 1 to 6; andp is an integer of 1 to 5. These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.
